Breast Cancer 2012 – New Aspects
Identifieur interne : 002B42 ( Pmc/Checkpoint ); précédent : 002B41; suivant : 002B43Breast Cancer 2012 – New Aspects
Auteurs : H.-C. Kolberg ; D. Lüftner ; M. P. Lux ; N. Maass ; F. Schütz ; P. A. Fasching ; T. Fehm ; W. Janni ; S. KümmelSource :
- Geburtshilfe und Frauenheilkunde [ 0016-5751 ] ; 2012.
Abstract
Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials.
Url:
DOI: 10.1055/s-0032-1315131
PubMed: 25324576
PubMed Central: 4168404
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4168404Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Breast Cancer 2012 – New Aspects</title><author><name sortKey="Kolberg, H C" sort="Kolberg, H C" uniqKey="Kolberg H" first="H.-C." last="Kolberg">H.-C. Kolberg</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Luftner, D" sort="Luftner, D" uniqKey="Luftner D" first="D." last="Lüftner">D. Lüftner</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Lux, M P" sort="Lux, M P" uniqKey="Lux M" first="M. P." last="Lux">M. P. Lux</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Maass, N" sort="Maass, N" uniqKey="Maass N" first="N." last="Maass">N. Maass</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Schutz, F" sort="Schutz, F" uniqKey="Schutz F" first="F." last="Schütz">F. Schütz</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Fasching, P A" sort="Fasching, P A" uniqKey="Fasching P" first="P. A." last="Fasching">P. A. Fasching</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Fehm, T" sort="Fehm, T" uniqKey="Fehm T" first="T." last="Fehm">T. Fehm</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Kummel, S" sort="Kummel, S" uniqKey="Kummel S" first="S." last="Kümmel">S. Kümmel</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25324576</idno><idno type="pmc">4168404</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168404</idno><idno type="RBID">PMC:4168404</idno><idno type="doi">10.1055/s-0032-1315131</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000051</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000051</idno><idno type="wicri:Area/Pmc/Curation">000051</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000051</idno><idno type="wicri:Area/Pmc/Checkpoint">002B42</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002B42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Breast Cancer 2012 – New Aspects</title><author><name sortKey="Kolberg, H C" sort="Kolberg, H C" uniqKey="Kolberg H" first="H.-C." last="Kolberg">H.-C. Kolberg</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Luftner, D" sort="Luftner, D" uniqKey="Luftner D" first="D." last="Lüftner">D. Lüftner</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Lux, M P" sort="Lux, M P" uniqKey="Lux M" first="M. P." last="Lux">M. P. Lux</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Maass, N" sort="Maass, N" uniqKey="Maass N" first="N." last="Maass">N. Maass</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Schutz, F" sort="Schutz, F" uniqKey="Schutz F" first="F." last="Schütz">F. Schütz</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Fasching, P A" sort="Fasching, P A" uniqKey="Fasching P" first="P. A." last="Fasching">P. A. Fasching</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Fehm, T" sort="Fehm, T" uniqKey="Fehm T" first="T." last="Fehm">T. Fehm</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Kummel, S" sort="Kummel, S" uniqKey="Kummel S" first="S." last="Kümmel">S. Kümmel</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></analytic><series><title level="j">Geburtshilfe und Frauenheilkunde</title><idno type="ISSN">0016-5751</idno><idno type="eISSN">1438-8804</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the
ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Geburtshilfe Frauenheilkd</journal-id><journal-id journal-id-type="iso-abbrev">Geburtshilfe Frauenheilkd</journal-id><journal-id journal-id-type="doi">10.1055/s-00000020</journal-id><journal-title-group><journal-title>Geburtshilfe und Frauenheilkunde</journal-title></journal-title-group><issn pub-type="ppub">0016-5751</issn><issn pub-type="epub">1438-8804</issn><publisher><publisher-name>Georg Thieme Verlag KG</publisher-name><publisher-loc>Stuttgart · New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25324576</article-id><article-id pub-id-type="pmc">4168404</article-id><article-id pub-id-type="doi">10.1055/s-0032-1315131</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Breast Cancer 2012 – New Aspects</article-title><trans-title-group xml:lang="de"><trans-title>Mammakarzinom 2012 – neue Aspekte</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kolberg</surname><given-names>H.-C.</given-names></name><xref rid="AF512-1" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Lüftner</surname><given-names>D.</given-names></name><xref rid="AF512-2" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Lux</surname><given-names>M. P.</given-names></name><xref rid="AF512-3" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Maass</surname><given-names>N.</given-names></name><xref rid="AF512-4" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Schütz</surname><given-names>F.</given-names></name><xref rid="AF512-5" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Fasching</surname><given-names>P. A.</given-names></name><xref rid="AF512-6" ref-type="aff"></xref><xref rid="CO-1" ref-type="author-notes"></xref></contrib><contrib contrib-type="author"><name><surname>Fehm</surname><given-names>T.</given-names></name><xref rid="AF512-7" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Janni</surname><given-names>W.</given-names></name><xref rid="AF512-8" ref-type="aff"></xref></contrib><contrib contrib-type="author"><name><surname>Kümmel</surname><given-names>S.</given-names></name><xref rid="AF512-9" ref-type="aff"></xref></contrib></contrib-group><aff id="AF512-1"><label>1</label><institution>Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop, Bottrop</institution></aff><aff id="AF512-2"><label>2</label><institution>Medizinische Klinik und Poliklinik II, Campus Charité Mitte, Berlin</institution></aff><aff id="AF512-3"><label>3</label><institution>Frauenklinik, Universitätsklinikum Erlangen, Erlangen</institution></aff><aff id="AF512-4"><label>4</label><institution>Department of Gynecology and Obstetrics, University Hospital Aachen</institution></aff><aff id="AF512-5"><label>5</label><institution>Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg</institution></aff><aff id="AF512-6"><label>6</label><institution>Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen</institution></aff><aff id="AF512-7"><label>7</label><institution>Department of Obstetrics and Gynecology, University Tübingen, Tübingen</institution></aff><aff id="AF512-8"><label>8</label><institution>Frauenklinik, Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf</institution></aff><aff id="AF512-9"><label>9</label><institution>Klinik für Senologie, Kliniken Essen-Mitte, Essen</institution></aff><author-notes><corresp id="CO-1"><bold>Correspondence </bold>Prof. Peter A. Fasching, MD <institution>University Hospital Erlangen, Department of Gynecology and Obstetrics</institution><addr-line>Universitätsstraße 21–23</addr-line><addr-line>91054 Erlangen</addr-line><email>peter.fasching@uk-erlangen.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2012</year></pub-date><volume>72</volume><issue>7</issue><fpage>602</fpage><lpage>615</lpage><history><date date-type="received"><day>18</day><month>6</month><year>2012</year></date><date date-type="rev-recd"><day>23</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2012</year></date></history><permissions><copyright-statement>© Thieme Medical Publishers</copyright-statement></permissions><abstract><p>Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the
ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials.</p></abstract><trans-abstract xml:lang="de"><sec><title>Zusammenfassung</title><p>Die Behandlungsoptionen und auch die Charakteristika zur Therapieentscheidung der Patientin mit einem primären und fortgeschrittenen Mammakarzinom werden immer vielfältiger. Neue zielgerichtete Therapien in Kombination mit etablierten Chemotherapien erweitern das Spektrum, doch potenziell vielversprechende Kombinationen bringen nicht immer ein besseres Ergebnis. Neueste Daten aus der Pharmakogenomik weisen auf Prognose- und Prädiktivfaktoren hin, die nicht nur die Eigenschaften des Tumors, sondern auch die vererbbaren genetischen Eigenschaften der Patientin berücksichtigen. Die aktuelle Therapieentscheidung ist somit mittlerweile eine Kombination aus klassischerweise klinischen und modernen molekularen Biomarkern. Immer häufiger werden auch gesundheitsökonomische Aspekte berücksichtigt, sodass auch gesundheitspolitische Überlegungen eine Rolle spielen können. Dieser Übersichtsartikel baut auf den aktuellen Kongressen auf, die jedes Jahr stattfinden. Die letzten
berücksichtigten sind hierbei das 34. San Antonio Breast Cancer Symposium und das ASCO Annual Meeting 2012. Zu deren Highlights zählten die klinisch bedeutsamen Ergebnisse der Studien CLEOPATRA, BOLERO-2, EMILIA und SWOG S0226 zur Therapie des metastasierten Mammakarzinoms sowie weitere aktuelle Daten zum adjuvanten Einsatz der Bisphosphonate im Rahmen der Studien ABCSG-12, ZO-FAST, NSABP-B34 und GAIN.</p></sec></trans-abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>CLEOPATRA</kwd><kwd>pertuzumab</kwd><kwd>BOLERO-2</kwd><kwd>everolimus</kwd><kwd>EMILIA</kwd><kwd>TDM-1</kwd><kwd>ABCSG-12</kwd><kwd>ZO-FAST</kwd><kwd>NSABP-B34</kwd><kwd>GAIN</kwd></kwd-group><kwd-group xml:lang="de"><title>Schlüsselwörter</title><kwd>CLEOPATRA</kwd><kwd>Pertuzumab</kwd><kwd>BOLERO-2</kwd><kwd>Everolimus</kwd><kwd>EMILIA</kwd><kwd>TDM-1</kwd><kwd>ABCSG-12</kwd><kwd>ZO-FAST</kwd><kwd>NSABP-B34</kwd><kwd>GAIN</kwd></kwd-group></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Fasching, P A" sort="Fasching, P A" uniqKey="Fasching P" first="P. A." last="Fasching">P. A. Fasching</name><name sortKey="Fehm, T" sort="Fehm, T" uniqKey="Fehm T" first="T." last="Fehm">T. Fehm</name><name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name><name sortKey="Kolberg, H C" sort="Kolberg, H C" uniqKey="Kolberg H" first="H.-C." last="Kolberg">H.-C. Kolberg</name><name sortKey="Kummel, S" sort="Kummel, S" uniqKey="Kummel S" first="S." last="Kümmel">S. Kümmel</name><name sortKey="Luftner, D" sort="Luftner, D" uniqKey="Luftner D" first="D." last="Lüftner">D. Lüftner</name><name sortKey="Lux, M P" sort="Lux, M P" uniqKey="Lux M" first="M. P." last="Lux">M. P. Lux</name><name sortKey="Maass, N" sort="Maass, N" uniqKey="Maass N" first="N." last="Maass">N. Maass</name><name sortKey="Schutz, F" sort="Schutz, F" uniqKey="Schutz F" first="F." last="Schütz">F. Schütz</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002B42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:4168404
|texte= Breast Cancer 2012 – New Aspects
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:25324576" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |